Crinetics Pharmaceuticals EBITDA 2017-2024 | CRNX

Crinetics Pharmaceuticals EBITDA for the quarter ending September 30, 2024 was $-0.091B, a 51.03% increase year-over-year.

  • Crinetics Pharmaceuticals 2023 EBITDA was -0.228B, a 36.51% increase from 2022.
  • Crinetics Pharmaceuticals 2022 EBITDA was -0.167B, a 56.89% increase from 2021.
  • Crinetics Pharmaceuticals 2021 EBITDA was -0.106B, a 43.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Crinetics Pharmaceuticals EBITDA 2017-2024 | CRNX

  • Crinetics Pharmaceuticals 2023 EBITDA was -0.228B, a 36.51% increase from 2022.
  • Crinetics Pharmaceuticals 2022 EBITDA was -0.167B, a 56.89% increase from 2021.
  • Crinetics Pharmaceuticals 2021 EBITDA was -0.106B, a 43.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.